Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development

Kuhn, A. J., Outlaw, V. K., Marcink, T. C., Yu, Z., Mears, M. C., Cajimat, M. N., Kreitler, D. F., Cleven, P. R., Mook, J. C., Bente, D. A., Porotto, M., Gellman, S. H., & Moscona, A. (2025). Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development. Journal of Virology. https://doi.org/10.1128/jvi.02159-24
Authors:
Ariel J Kuhn
Victor K Outlaw
Tara C Marcink
Zhen Yu
Megan C Mears
Maria N Cajimat
Dale F Kreitler
Payton R Cleven
Jee Ching Mook
Dennis A Bente
Matteo Porotto
Samuel H Gellman
Anne Moscona
Affiliated Authors:
Tara C Marcink
Matteo Porotto
Anne Moscona
Columbia Affiliation:
Subjects:
Coronavirus Disease 2019 Research (OpenAlex Topic)
Influenza Virus Research and Epidemiology (OpenAlex Topic)
Epidemiology and Pathogenesis of Respiratory Viral Infections (OpenAlex Topic)
Author Keywords:
sars-cov-2
lipopeptide
solubility
inhibitors
viral fusion
heptad repeats
crystal structure
peptide design
antiviral
elink
Publication Type:
Article
Unique ID:
10.1128/jvi.02159-24
PMID:
39902960
DOI:
10.1128/jvi.02159-24
Journal:
Journal of Virology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View OpenAlex Record
View Web of Science Record
View Scopus Record

Record Created: